argenx SE Investor Day Presentation Deck slide image

argenx SE Investor Day Presentation Deck

Neuromuscular Franchise: A Company within a Company IIP Programs argenx ARGX-119 SIMPLE AntibodyTM aimed to boost the neuromuscular junction in disease ARGX-117 C2 inhibitor Efgartigimod FcRn antagonist Leveraging infrastructure across multiple indications and molecules ALS MG 2021 SMA MMN Myositis CIDP MG MUSK MG MG-SC 2022 Congenital MG MMN Myositis CIDP 2023 - 2026 13
View entire presentation